The angiogenesis inhibitor bevacizumab (Avastin) failed to increase overall survival or statistically significant progression-free survival for glioblastoma patients in the frontline setting, according to a study led by researchers at the University of Texas MD Anderson Cancer Center.
Fuente : http://www.eurekalert.org/pub_releases/2014-02/uot...
Fuente : http://www.eurekalert.org/pub_releases/2014-02/uot...